Top Markets
#1 Decred Decred +10.19%
#2 Wibx Wibx +9.06%
#3 Status Status +7.37%
#4 aelf aelf +5.49%
#5 SkyAI SkyAI +4.75%
#6 MarsCoin MarsCoin +4.32%
#7 Rei Rei +4.03%
#8 Robinhood Wrapped ETH (Robinhood Chain) Robinhood Wrapped ETH (Robinhood Chain) +3.86%
#9 TRIA TRIA +3.71%
#10 Humanity Humanity +3.23%
Coin of the day
Decred Decred
Settings
Language
ENGLISH
Currency
USD
Theme
Xcell Therapeutics, Inc. Xcell Therapeutics, Inc.

Xcell Therapeutics, Inc.

373110
Rank in Stocks #30680
Xcell Therapeutics Inc. engages in the development and production of drugs for... Xcell Therapeutics Inc. engages in the development and production of drugs for cell therapy. It offers CellCor, a serum-free chemically defined medium that is used to develop human mesenchymal stem cells. The company also offers XPorT, a platform that aims to develop optimal media from the perspective of the user using a variety of cells. In addition, it develops media for cell culture in various areas of the bioindustry such as cell therapy, gene therapy, exosomes, organoids and bioreactors. Xcell Therapeutics Inc. was founded in 2015 and is based in Seoul, South Korea.
Share Price
$0.91968646
Last synced: 2026-08-18
Market Cap
$15.91M
Change (1 day)
2.23%
Change (1 year)
-52.75%
Country
KR
Trade Xcell Therapeutics, Inc. (373110)

Category

Healthcare
Revenue for Xcell Therapeutics, Inc. (373110)
Revenue in Aug 2026 TTM: 0
According to Xcell Therapeutics, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Xcell Therapeutics, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE